CDK19 and AL amyloidosis: A kinase-wide RNAi lethality study using high-through kinome siRNA screening identified CDK11 as a vulnerable kinase in human multiple myeloma, which proposes that inhibition of CDK11 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma [22].